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Summary. Background: Acute myocardial infarction (AMI)
is rare among young women. The search for unknown risk
factors is warranted. Endothelial protein C receptor (EPCR)
is largely present at the endothelial surface of large arteries.
No studies about association of anti-EPCR autoantibodies
(anti-EPCR) with AMI are available. Methods: Plasma IgA,
IgM and IgG anti-EPCR levels were measured by enzyme-
linked immunosorbent assay in 165 women younger than
45 years who survived a first AMI and 165 healthy women,
matched by age and geographical origin. Results: Using the
90th percentile of IgA anti-EPCR in the control group, IgA
anti-EPCR were independently associated with AMI after
adjustment for cardiovascular risk factors (OR 5.1; 95% CI
1.7–15.6; P ¼ 0.004). The risk apparently conferred by IgA
anti-EPCR increased dose-dependently (P for trend ¼
0.0002). IgM anti-EPCR were less consistently associated
with AMI: a significant increase in the risk was found when
women above the 90th percentile were compared with those
in the lowest quartile (OR 3.6; 95% CI 1.2–11.5; P ¼ 0.03).
IgG anti-EPCR were similar in patients and controls. A
total of 145 patients underwent coronary arteriography. IgA
or IgM anti-EPCR were not different among patients with
different degrees of atherosclerotic lesion (ANOVA, P ¼ 0.77
and 0.24, respectively). Conclusions: High levels of IgA and,
to a lesser extent, IgM anti-EPCR, are associated with AMI in
young women.
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Introduction
Acute myocardial infarction (AMI) is a rare event in young
women. Traditional risk factors for atherosclerosis are usually
less prominent in this population, and do not account for a
large proportion of cases. For this reason, the search for new
pathogenetic mechanisms is warranted. Coronary heart disease
(CHD) is an inflammatory process which involves cellular and
molecular responses to endothelial dysfunction [1], and recently
autoimmune disorders have been demonstrated to increase the
risk of premature atherothrombosis [2–7].
Endothelial protein C/activated protein C receptor (EPCR)
is an endothelial membrane glycoprotein able to bind both
protein C and activated protein C (APC) with high affinity [8].
Protein C, when bound to EPCR, is activated more efficiently
by the thrombin–thrombomodulin complex on the endothelial
surface [9]. APC is a major inhibitor of blood coagulation and
strong evidence supports a role for APC in anti-inflammatory/
antiapoptotic mechanisms [10,11]. Recently, we have demon-
strated the presence of anti-EPCR autoantibodies in a group of
patients with thrombosis and autoimmune diseases [12]. The
fact that EPCR is mainly expressed in large vessels, especially
arteries [13], prompted us to investigate the presence of anti-
EPCR autoantibodies in AMI. As the occurrence of autoim-
mune disorders is more frequent in women than in men, the
association of anti-EPCR autoantibodies with a first AMI
event was investigated in women under the age of 45 years in a
matched case–control study. We demonstrate that IgA and
IgM anti-EPCR autoantibodies are observed with a higher
frequency in women who had developed AMI than in controls,
and that high levels of these autoantibodies are independent
risk factors for AMI in young women.
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Methods
Patients and controls
The participants in this study were from the ongoing Italian
nationwide case–control study on premature AMI conducted
by the Atherosclerosis, Thrombosis, and Vascular Biology
Italian Study Group and described elsewhere [14]. Cases were
165 women hospitalized for a first AMI at an age of 45 years or
less. They had no history of venous or arterial thrombosis.
Controls were 165 healthy women unrelated to the cases,
without thrombotic antecedents, individually matched with the
cases by age and region of origin, within a range of ±3 years.
The cases and controls were enrolled between January 1998
and January 2003.
The Institutional Review Boards of the participating hospi-
tals approved the study. All the participants gave their written
informed consent and agreed to give blood samples for plasma
measurements. Both cases and controls were administered a
questionnaire on traditional cardiovascular risk factors. The
collected data included age, height, weight, hypertension,
diabetes, family history of CHD, age of menopause, estrogen
use, smoking, total cholesterol, HDL cholesterol and tri-
glycerides. The data on cases were collected from 3 to
12 months after their first AMI, while those pertaining to
controls were obtained at the time of the hospital evaluation for
study enrolment. Definitions of AMI and traditional risk
factors have been described in detail [14]. The degree of
coronary stenosis was evaluated by angiography and defined as
follows: normal, when no narrowing was observed; non-
significant stenosis, in case of a narrowing <70% (50% in the
case of the left main coronary artery); severe stenosis, when a
narrowing >70% (50% in the case of the left main coronary
artery) was observed.
Blood collection
Blood collection took place from 3 to 12 months after AMI.
Blood was withdrawn from an anticubital vein into evacuated
tubes containing 0.129 mol L)1 trisodium citrate. Platelet-poor
plasma was obtained by double centrifugation at 3000 g for
20 min and was kept at )70 C until the assays were carried
out.
Expression and purification of soluble EPCR
Soluble EPCR (sEPCR) fused with myc epitope and a six His
tag at its C-terminal end was expressed in Pichia pastoris strain
X-33 using the EasySelect Pichia expression kit (Invitrogen,
Paisley, UK) and purified as described [12].
Assay for anti-EPCR autoantibodies detection
Anti-EPCR autoantibodies of IgM and IgG isotypes were
measured using a previously described enzyme-linked immu-
nosorbent assay [12]. To detect anti-EPCR of IgA isotype a
peroxidase-conjugated murine Mo Ab antihuman IgA
(BioTrend, Cologne, Germany) was used.
Ability of autoantibodies to prevent protein C activation on
the endothelial surface
When enough volumes of samples displaying high levels of anti-
EPCR were available, the immunoglobulins were purified and
their ability to prevent proteinC activation on endotheliumwas
tested according to previously described procedures [12].
Statistical methods
In this matched case–control study, comparison between cases
and controls for continuous and categorical variables was
performed with a t-test for paired samples and McNemar test,
respectively. Association between continuous variables and
anti-EPCR antibodies was assessed with the Spearman corre-
lation coefficient. A conditional logistic regression analysis with
matchedpairs of cases and controlswasused to evaluate the risk
of AMI associated with high levels of IgA, IgG and IgM anti-
EPCR.Themain independent variableswere levels of IgA, IgG,
and IgM anti-EPCR categorized according to the distribution
of anti-EPCR in the control group.Univariate andmultivariate
analysiswere performedadjusting for traditional risk factors for
AMI.The levels of anti-EPCRautoantibodieswere alsodivided
in quartiles to assess whether or not there was dose–response
relationshipwith the risk ofAMI.Tests for trend inAMI across
quartiles of anti-EPCR were evaluated in conditional logistic
models using a continuous variable with the median values for
each quartile of the antibodies. Product-terms were introduced
in the conditional logistic models to analyze interaction (effect
modification). Finally, the relationship between levels of anti-
EPCR autoantibodies and coronary stenosis was assessed by
ANOVA, to compare levels of anti-EPCR according to the
categories of stenosis. We also dichotomized the degree of
coronary stenosis as no stenosis vs. moderate or severe stenosis
and used a non-conditional logistic regressionmodel to seek for
differences in anti-EPCR levels between groups.
Results
The case sample consisted of 165 women, who were
22–45 years old (median age: 40 years) at the time of the first
AMI. Twenty-two percent had normal coronary arteriograms,
15% non-significant stenosis, and 63% significant stenosis.
IgA anti-EPCR
The median [inter-quartile range (IQR)] value of IgA anti-
EPCR level was 10.7 (4.3–19.5) arbitrary units (AU) for
controls and 15.7 (9.4–27.4) AU for patients. The 90th
percentile of the IgA anti-EPCR in controls was 28.8 AU,
and 36 of 165 patients (22%) had values exceeding this cut-off,
compared with 17 of 165 controls (10%). The crude odds ratio
(OR) for AMI in women with IgA anti-EPCR above the 90th
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percentile was 2.8 [95% confidence interval (CI) 1.4–5.6; P ¼
0.003]. A multivariate analysis adjusting for traditional cardio-
vascular risk factors was subsequently carried out. Table 1
shows the frequency distribution and the unadjusted and
adjusted ORs for anti-EPCR autoantibodies together with
frequencies and ORs for the traditional risk factors. After
adjustment for the latter, the OR for AMI in women with IgA
anti-EPCR above the 90th percentile increased to 5.1 (95% CI
1.7–15.6; P ¼ 0.004). Thus, IgA anti-EPCR levels above the
90th percentile were independently associated with AMI in
young women. To analyze if the relative risk associated with
IgA anti-EPCR increased in a dose-dependent fashion, patients
were categorized in quartiles according to the IgA anti-EPCR
levels in controls, and the OR for AMI was calculated for each
of the three upper quartiles using the lowest quartile as the
reference. Table 2 shows that the adjusted OR increased
steadily with the IgA anti-EPCR levels, suggesting a dose–
response effect (P for trend ¼ 0.0002).
IgM anti-EPCR
The median (IQR) of IgM anti-EPCR levels was 20.7 (11.3–
33.6) and 20.2 (11.2–39.9) for controls and cases, respectively.
When the patients were categorized in quartiles, women with
levels above the 90th percentile (>49 AU) compared with
those in the lowest quartile (<11 AU) had a statistically
significant increase in their risk (OR 3.6; 95% CI 1.2–11.5;
P ¼ 0.03). Thus, it appears that the association with AMI is
only increased in women with high levels of IgM anti-EPCR
(i.e. with a threshold effect).
There was no correlation between IgA and IgM anti-EPCR
levels in controls (Spearman q ¼ 0.047, n ¼ 165), in patients
(Spearman q ¼ 0.016, n ¼ 165), or when all the individu-
als included in the study were taken together (Spearman q ¼
0.035, n ¼ 330). No interaction could be seen among the
analyzed variables (likelihood ratio test, P > 0.05).
IgG anti-EPCR
High levels of IgG anti-EPCR autoantibodies could be
detected in one patient and one control but there were no
differences between cases and controls for IgG anti-EPCR
autoantibodies (not shown).
Relationship to coronary stenosis
A total of 145 of 165 patients underwent coronary arteriog-
raphy: 32 (22%) showed no lesion, 22 (15%) showed a non-
significant stenosis and 91 (63%) showed a severe stenosis. We
evaluated whether or not the presence of high levels of anti-
EPCR autoantibodies was associated with the degree of
coronary artery stenosis. Neither IgA nor IgM anti-EPCR
levels were significantly different across the groups, as assessed
by ANOVA (P ¼ 0.77 and 0.24, respectively). The comparison
between patients without stenosis (n ¼ 32) and patients with
stenosis (n ¼ 113) showed also non-significant differences
when adjusting for traditional risk factors (data not shown).
Effect of anti-EPCR autoantibodies on protein C activation
We observed no effect of the immunoglobulin fractions
purified from the samples displaying the highest IgA (n ¼ 9)
Table 1 Association of anti-EPCR autoantibodies and traditional risk factors with acute myocardial infarction (AMI) in young women
Characteristic Patients, n (%) Controls, n (%) Unadjusted OR (95% CI) Adjusted OR (95% CI) P
IgA anti-EPCR 36 (22)* 17 (10)* 2.8 (1.4–5.6) 5.1 (1.7–15.6) 0.004
IgM anti-EPCR 26 (16)* 17 (10)* 1.8 (0.9–3.5) 2.0 (0.4–9.7) 0.080
Hypertension 38 (23) 12 (7) 4.2 (2.0–9.2) 5.4 (1.6–18.5) 0.007
Family history of CHD 49 (30) 14 (8) 5.0 (2.4–10.0) 4.4 (1.5–13.1) 0.008
Smoking 126 (76) 81 (49) 3.4 (2.0–5.6) 6.0 (2.5–14.2) <0.001
Diabetes 9 (5) 2 (1) 8.0 (1.0–64.0) 1.9 (0.2–19.5) 0.590
Menopause 11 (7) 1 (1) 11.0 (1.4–85.2) 12.1 (0.9–163.9) 0.060
Estrogen use 66 (40) 49 (30) 1.7 (1.0–2.8) 1.3 (0.5–2.9) 0.590
HDL/cholesterol 0.246 (0.095) 0.302 (0.098) 1.7 (1.3–2.2) 1.4 (0.9–2.2) 0.120
Triglycerides 133 (84) 96 (41) 2.1 (1.6–2.8)§ 1.8 (1.2–2.7)§ 0.003
EPCR, endothelial protein C receptor; CHD, coronary heart disease. Number of events (percentages in brackets) in patients and controls are
indicated; odds ratios (OR) before and after adjustment for traditional risk factors associated with AMI are also shown. Anti-EPCR autoanti-
bodies are categorized using the 90th percentile for the variable in the control group as the cut-off point. P corresponds to the adjusted OR, which
are adjusted for all the variables presented in the table and BMI (including a lineal and quadratic term). *Number of patients (percentages in
brackets) with values of anti-EPCR autoantibodies above the 90th percentile. Mean (standard deviation). Risk associated with decrease in each
0.1 units of the ratio. §Risk associated with increase in each 50 mg dL)1.
Table 2 Association with acute myocardial infarction (AMI) according to
the IgA anti-EPCR autoantibody levels
Cases/
controls, n
Adjusted
OR (95% CI)
P for
trend
Q1, <4 AU 19/42 1 (reference) <0.001
Q2, 4–10 AU 33/39 7.7 (2.0–29.6) NA
Q3, 11–19 AU 44/43 8.1 (2.3–27.9) NA
Q4, >19 AU 69/41 13.7 (4.0–46.9) NA
EPCR, endothelial protein C receptor; NA, not applicable. Patients
and controls were stratified in quartiles according to the IgA anti-
EPCR level. Odds ratios (OR) for AMI were calculated in the second
(Q2), third (Q3), and fourth (Q4) quartiles, as compared with those in
the first (Q1) quartile. Adjustment for risk factors associated with AMI
was performed.
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and IgM (n ¼ 11) anti-EPCR levels on the activation of
protein C on the endothelial surface (not shown).
Discussion
The association of anti-EPCR autoantibodies with AMI has
been demonstrated for the first time in this study. We provide
evidence that IgA anti-EPCRautoantibodies are independently
associated with a first AMI in young women. This population
of patients was chosen because autoimmune disorders aremore
frequently found in women than in men and because the
prevalence of the classical risk factors is lower in this group [15].
In case of IgA anti-EPCR, levels above the 90th percentile
increased fivefold the relative risk for AMI after adjustment for
traditional risk factors (i.e. hypertension, familial history,
smoking, diabetes, menopause, cholesterol and triglycerides)
and estrogen use. Themagnitude is similar to the risk conferred
by hypertension and a family history of CHD and was dose-
dependent. High levels of IgM anti-EPCR were also inde-
pendently associated with AMI but less consistently, and more
weakly than IgA. No differences could be seen in IgG anti-
EPCR levels. The different association between different
isotypes (IgA but not IgG) and the risk of coronary events
has previously been described for anti-heat-shock protein
60 [16,17]. This apparently surprising finding could be
explained by an infection of a mucosal tissue. Several lines of
evidence associate infection, autoimmunity and arterial disease
[18,19]. If the infective agent involved mucosal tissues, an IgA
response would be triggered, which could display a cross-
reaction with an autoantigen.
Unlike other autoantibodies like anticardiolipin or anti-
b2-glycoprotein I, whose pathogenic mechanisms are poorly
understood, anti-EPCR autoantibodies can reasonably be
thought to play a causative role in arterial thrombosis. As
EPCR is a receptor specifically located at the intima, immune
complexes will deposit on the arterial wall. As a result
antibody-dependent cellular cytotoxicity [20] or local activation
of the complement system [21,22] may occur. The anti-EPCR
autoantibodiesmay also impair theAPC generation [12], which
may lead to increased thrombin generation, inflammation and
apoptosis [11,23], although this property does not seem to be
the case in the present study. Finally, as anti-EPCR auto-
antibodies are not associated with the degree of coronary
stenosis, they would be involved in the acute event rather than
in the progression of atherosclerotic plaque.
This study has limitations. Even though the cases were
studied andblood samples obtained at a distance from the acute
episode, when they could be considered to be in a relatively
stable condition, it cannot be ruled out that high anti-EPCR
titers are the expression of a reaction to disease, and hence the
consequence rather than the cause of AMI. Another limit of
this retrospective study is that women who died after AMI
could not be investigated, so that we cannot exclude the
possibility that these patients may have had a specially high
proportion of high anti-EPCRvalues.As this is the first attempt
to study the anti-EPCR autoantibodies in patients with AMI,
the possibility that the association has arisen by chance cannot
be ruled out and new studies are necessary to confirm these
findings. On the other hand, as we have studied a group of
patients, women under 45 years, which might have an autoim-
munity background, the possibility that other autoantibodies
were present in this population should be taken into account.
In conclusion we found that high levels of IgA and, to a
lesser extent, IgM anti-EPCR autoantibodies are independ-
ently associated with AMI in young women. It remains to be
established whether or not these antibodies are associated with
cardiovascular disease in other populations.
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